Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eplerenone - Pfizer

Drug Profile

Eplerenone - Pfizer

Alternative Names: CGP 30083; Epoxymexrenone; Inspra; SC 66110; Selara

Latest Information Update: 27 May 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Medical University of Graz; Pfizer; Solvotrin Innovations
  • Class Antihypertensives; Heart failure therapies; Lactones; Pregnenes; Small molecules
  • Mechanism of Action Aldosterone receptor antagonists; Potassium-sparing diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Heart failure; Hypertension
  • Discontinued Chronic heart failure; Left ventricular dysfunction; Postmyocardial infarction; Primary hyperparathyroidism

Most Recent Events

  • 08 Apr 2021 Discontinued - Phase-III for Chronic heart failure in Japan, Argentina, Australia, Asia, North America, Europe (PO) (Pfizer pipeline, April 2021)
  • 08 Apr 2021 Discontinued - Phase-III for Postmyocardial infarction in France, Netherlands, United Kingdom, Greece, Germany, Slovakia, Hungary, Canada, Czech Republic, Poland, Spain (PO) (Pfizer pipeline, April 2021)
  • 08 Apr 2021 Discontinued - Phase-II for Left ventricular dysfunction in Ireland (PO) (Pfizer pipeline, April 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top